• SyncroPatch 384

    Next level versatility and flexibility
  • SyncroPatch 384

    True HTS and GigaOhm seals
  • SyncroPatch 384

    Your multi purpose instrument
  • SyncroPatch 384

    Powerful analysis software
  • SyncroPatch 384

    Assay flexibility via high tech
  • SyncroPatch 384

    Heating and cooling of solutions, cells and patch clamp sites

12.10.2020 | Webinar: The Sodium Channel Network Aachen meets the SyncroPatch

icon sp96  SyncroPatch 384i Webinar

Date: October 12. 2020, 2:00 PM CET (8:00 AM EDT)

201012 Blog Image VUM 2020


Prof. Dr. med. Angelika Lampert (RWTH Aachen University, Institute of Physiology (Neurophysiology))

This is an on-demand webinar from Nan]i[on and Friends 2020.


Chronic pain is severely affecting patients and society, and affected individuals often are so harshly restricted that they cannot participate in everyday life or hold a job. Research on chronic pain was boosted when mutations in voltage-gated sodium channels were identified which either lead to gain- or loss-of-pain in humans. In Aachen we founded the Sodium Channel Network Aachen (SCNAachen) in which we aim to tackle Nav related chronic pain in patients suffering from small fiber neuropathy (SFN). Our efforts to understand the biophysical impact of a mutation and, most notably, to identify individual personalized treatment for the pain patients in our SFN cohort, are now excelled by the availability of a SynchroPatch. We focus on pain-related Nav1.7 or Nav1.8 mutants identified in our patient cohort recently. We aim to i) identify mutation-induced Nav gating changes, ii) to find personalized medicine by screening a library of approved drugs and iii) to open research on pig DRGs and potentially also human iPS-cell derived sensory neurons for high throughput electrophysiology by optimizing their preparation. Thus, with the availability of the SyncroPatch, the SCNAachen aims to demonstrate the immense potential of high-throughput electrophysiology in a multidisciplinary way by combining the comprehensive biophysical characterization of Nav mutants with high-throughput drug screening and hit validation in patient-derived sensory neurons. This enables us to link basic research on the dynamic structure-function relationship of Navs to clinical translation by exploring variant-specific targeted drug therapy.

Back to Overview


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.